03.07.2020
康方生物董事长兼首席执行官夏瑜女士入选2020福布斯“中国科技女性榜”
25.05.2020
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
11.05.2020
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
Who We Are?
About Us

Akeso,Inc.(HKEX Code: 9926.HK) is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. The Company dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Akeso’s vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.
 
The Company’s business is designed to drive success through both efficient and breakthrough R&D innovation. Since its inception, the Company has had the foresight to develop an end-to-end platform, Akeso Comprehensive Exploration platform (“ACE Platform”), encompassing comprehensive drug discovery and development functionalities, including target validation, antibody drug discovery and development, CMC, and GMP-compliant manufacturing...

Collaborations
Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

图层 0 (4) logo图层 2 (1) logo图层 1 (1) logo图层 3 (1) logo图层 4 (1) logo
Pipelines
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

组 6 (2) logo